Markus A Schramm Nils Venhoff Dirk Wagner Jens Thiel Daniela Huzly Nils Craig-Mueller Marcus Panning Hartmut Hengel Winfried V Kern Reinhard E Voll
10.3389/fimmu.2020.02086
Front Immunol
2020 Aug 28;11:2086.
covid-19 egpa sars-cov-2 cyclophosphamide eosinophilic granulomatosis with polyangiitis immunosuppression rituximab vasculitis
CC BY
https://pubmed.ncbi.nlm.nih.gov/32983161/
Betacoronavirus / genetics Churg-Strauss Syndrome / complications Churg-Strauss Syndrome / drug therapy Coronavirus Infections / complications Cyclophosphamide / therapeutic use Granulomatosis with Polyangiitis / complications Granulomatosis with Polyangiitis / drug therapy Immunosuppressive Agents / therapeutic use Pneumonia, Viral / complications
Betacoronavirus / genetics Churg-Strauss Syndrome / complications Churg-Strauss Syndrome / drug therapy Coronavirus Infections / complications Cyclophosphamide / therapeutic use Granulomatosis with Polyangiitis / complications Granulomatosis with Polyangiitis / drug therapy Immunosuppressive Agents / therapeutic use Pneumonia, Viral / complications Case Reports Research Support, Non-U.S. Gov't Adult Antiviral Agents / therapeutic use COVID-19 Coronavirus Infections / drug therapy Coronavirus Infections / virology Drug Therapy, Combination Glucocorticoids / therapeutic use Humans Immunocompromised Host Male Pandemics Pneumonia, Viral / drug therapy Pneumonia, Viral / virology Prednisolone / therapeutic use RNA, Viral / genetics Reverse Transcriptase Polymerase Chain Reaction Rituximab / therapeutic use SARS-CoV-2 Treatment Outcome Antiviral Agents Glucocorticoids Immunosuppressive Agents RNA, Viral Rituximab Cyclophosphamide Prednisolone
PMC7484740
32983161
COVID-19 in a Severely Immunosuppressed Patient With Life-Threatening Eosinophilic Granulomatosis With Polyangiitis
2020